The importance of drug-drug interactions in the DAA era.
暂无分享,去创建一个
David Back | D. Back | L. Else | Laura Else
[1] M. Buti,et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. , 2013, Journal of hepatology.
[2] P. Marcellin,et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. , 2011, Gastroenterology.
[3] G. Everson,et al. Management of the transplant recipient with chronic hepatitis C. , 2013, Clinics in liver disease.
[4] M. Rodríguez-Torres. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient , 2012, Current opinion in infectious diseases.
[5] D. Samuel,et al. Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence , 2012, Antimicrobial Agents and Chemotherapy.
[6] Martin Fisher,et al. Current Opinion in Infectious Diseases: Editorial introductions , 2010 .
[7] V. Garg,et al. Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin , 2011, Antimicrobial Agents and Chemotherapy.
[8] Samir K. Gupta,et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers , 2012, Hepatology.
[9] E. O'Mara,et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] M. Sulkowski. HCV therapy in HIV‐infected patients , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[11] C. Berg,et al. Telaprevir‐based triple therapy in liver transplant patients with hepatitis C virus: A 12‐week pilot study providing safety and efficacy data , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[12] A. Molla,et al. 955 PRECLINICAL POTENCY, PHARMACOKINETIC AND ADME CHARACTERIZATION OF ABT-333, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR , 2009 .
[13] V. Garg,et al. Telaprevir: Pharmacokinetics and Drug Interactions , 2012, Antiviral therapy.
[14] J. Rockstroh,et al. HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients? , 2012, AIDS.
[15] M. Buti,et al. OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients , 2013 .
[16] K. Sherman,et al. Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline , 2012, Current HIV/AIDS Reports.
[17] W. Tong,et al. Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor , 2011, Drug Metabolism and Disposition.
[18] C. Flexner,et al. Direct-acting antiviral agents for hepatitis C virus infection. , 2013, Annual review of pharmacology and toxicology.
[19] V. Garg,et al. Review of Drug Interactions with Telaprevir and Antiretrovirals , 2013, Antiviral therapy.
[20] Jörg Huwyler,et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. , 2012, Biochemical pharmacology.
[21] V. Garg,et al. Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin , 2012, Journal of clinical pharmacology.
[22] M. Sulkowski. Current management of hepatitis C virus infection in patients with HIV co-infection. , 2013, The Journal of infectious diseases.
[23] F. Müller,et al. Transporter-mediated drug-drug interactions. , 2011, Pharmacogenomics.
[24] G. Everson,et al. Review and management of drug interactions with boceprevir and telaprevir , 2012, Hepatology.